Table 4.
One-Year Follow Up |
|||||
---|---|---|---|---|---|
Non-use (58.5%; n = 2,602) | General use (17.1%; n = 762) | Blunt and Cannabis use (15.0%; n = 665) | Concurrent and Co-administration use (9.4%; n = 419) | ||
Baseline | Non-use (57.8%; N = 2,572) | 0.95 | 0 | 0.05 | 0 |
General use (18.9%; N = 840) | 0.13 | 0.77 | 0.03 | 0.07 | |
Blunt and Cannabis use (13.2%; N = 585) | 0.14 | 0.03 | 0.80 | 0.03 | |
Concurrent and Co-administration use (10.1%; N = 451) | 0 | 0.17 | 0.08 | 0.74 | |
Three-Year Follow Up | |||||
Non-use (57.9%; n = 2,575) | General use (18.3%; n = 815) | Blunt and Cannabis use (14.9%; n = 662) | Concurrent and Co-administration use (8.9%; n | ||
One-Year Follow Up | Non-use (58.5%; N = 2,602) | 0.91 | 0.04 | 0.05 | 0 |
General use (17.1%; N = 762) | 0.04 | 0.85 | 0.05 | 0.05 | |
Blunt and Cannabis use (15.0%; N = 665) | 0.21 | 0 | 0.77 | 0.03 | |
Concurrent and Co-administration use (9.4%; N = 419) | 0 | 0.15 | 0.08 | 0.78 | |
Three-Year Follow Up | |||||
Non-use (57.9%; n = 2,575) | General use (18.3%; n = 815) | Blunt and Cannabis use (14.9%; n = 662) | Concurrent and Co-administration use (8.9%; n = 396) | ||
Baseline | Non-use (57.8%; N = 2,572) | 0.91 | 0.02 | 0.07 | 0 |
General use (18.9%; N = 840) | 0.11 | 0.78 | 0.04 | 0.07 | |
Blunt and Cannabis use (13.2%; N = 585) | 0.24 | 0.01 | 0.72 | 0.03 | |
Concurrent and Co-administration use (10.1%; N = 451) | 0.01 | 0.22 | 0.08 | 0.69 |
The one-year follow up measurement occasion occurred in the spring of 2017 and the three-year follow up in the spring of 2019.